Samyang Holdings Biopharm Group

Samyang Holdings Biopharm Group is the specialized healthcare division of the South Korean Samyang Group, focusing on oncology therapeutics and advanced drug delivery systems (DDS). The company is a global leader in the production of biodegradable surgical sutures and has successfully commercialized several oncology products using its proprietary polymeric micelle technology. Its flagship product, Genexol-PM, is a cremophor-free formulation of paclitaxel that improves safety and efficacy in treating breast and lung cancers. Samyang is currently leveraging its SENS (Samyang Effective Nanocarrier System) platform to develop next-generation mRNA therapeutics and gene delivery solutions. With a dedicated R&D presence in both South Korea and the United States, the group aims to expand its footprint in the global biopharmaceutical market through innovation in drug formulation and medical devices.